Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …

Pulmonary embolism is a common and potentially fatal cardiovascular disorder that must be
promptly diagnosed and treated. The diagnosis, risk assessment, and management of …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting
up to 5% of the population. VTE commonly manifests as lower-extremity deep venous …

Importance Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to
112 per 100 000 person-years and increase with age. Rates of recurrent VTE range from …

Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism,
is a chronic illness that affects nearly 10 million people every year worldwide. Strong …

Background: The incidence of pulmonary embolism has been increasing, but its case-fatality
rate is decreasing, suggesting a lesser severity of illness. The clinical importance of patients …

For patients with venous thromboembolism (VTE), prediction of bleeding is relevant
throughout the course of treatment, although the means and goal of this prediction differ …

Background In patients with noncirrhotic chronic portal vein thrombosis (PVT), the benefit of
long-term anticoagulation is unknown. We assessed the effects of rivaroxaban on the risk of …

The most important decision in the long-term treatment of venous thromboembolism (VTE) is
how long to anticoagulate. VTE provoked by a reversible risk factor, or a first unprovoked …